ARS Pharmaceuticals Inc (NASDAQ: SPRY) announces that the regulatory approval timeline for its nasal spray epinephrine product Neffy in Canada has been clarified.

According to the latest plan, the company expects to receive approval from Health Canada in the second quarter of 2026, followed by the official commercial launch of the product later in 2026. This development marks a key step for ARS Pharmaceuticals in expanding into the North American market. Neffy, as an innovative nasal spray delivery system, aims to provide a more convenient and rapid treatment option for patients with severe allergic reactions. If approved, it will become the first product of its kind on the Canadian market and is expected to change the current landscape of allergy emergency treatments that rely on injections. The company stated that it has reached a consensus with Canadian regulatory authorities regarding the approval pathway and will submit the relevant supplementary data as planned. The clarification of this timeline provides investors with a clear roadmap for product commercialization and also reflects the company's execution capability in advancing its global registration strategy.